Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Q4 FY25: Capex ₹15 Cr
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Current revenue is approximately ₹109 crore, with 15-20% from CRAMS projects. FY26 is expected to be a year of consolidation with moderate top-line growth and margin normalization to 24-26% range due to pricing pressures and ramp-up costs.
From Shree Ganesh Remedies Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Current revenue is approximately ₹109 crore, with 15-20% from CRAMS projects.
- Revenue is expected to double over the next 3-4 years, driven largely by CRAMS and new projects.
- CRAMS revenue will increase steadily, potentially doubling or tripling in the future.
- No single project contributes ₹100 crore currently; peak revenues for key projects are around ₹30-35 crore annually.
- Larger scale projects with volumes above 200-500 metric tons are in the pipeline, supporting growth.
- FY26 is expected to be a consolidation year with moderate top-line growth and margin normalization.
- CRAMS commercialization and approvals anticipated to support commercial supplies starting from mid-FY26 onwards.
2 more points from Shree Ganesh Remedies Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has invested significantly in R&D, infrastructure, and capacity over the last two years, focusing on projects they anticipate will commercialize in the near future.
- CapEx remains aggressive with ongoing construction of manufacturing Block 9 near Plant 8, and a new pilot plant near Plant 4 to support advanced chemistries including flow chemistry.
- Planned CapEx for FY26 is approximately ₹15 crore, mainly for manufacturing blocks and pilot plant.
- Development of common infrastructure and utilities at the Dahej site is underway to support large-scale CRAMS projects.
- Expansion at the Ankleshwar site is preferred for manufacturing infrastructure with ample space after acquiring neighboring land.
2 more points from Shree Ganesh Remedies Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is actively working on multiple custom synthesis (crams) projects, with 6 projects typically closed in the lab annually.
- Current crams revenue is approximately 15-20% of total revenue, expected to grow steadily over the next few years.
- The order book includes projects with peak volumes above 200 metric tons; e.g., agrochemical and Japanese projects targeting 250-500+ metric tons.
- New innovative multi-step complex products are in development with a few projects expected to generate annual revenues of 30-35+ crore at peak.
- No single project currently expected to add 100 crore in FY27; growth anticipated through a portfolio of small-to-medium projects.
2 more points from Shree Ganesh Remedies Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Rem's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Shree Ganesh Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q4 FY25 results?
Current revenue is approximately ₹109 crore, with 15-20% from CRAMS projects. FY26 is expected to be a year of consolidation with moderate top-line growth and margin normalization to 24-26% range due to pricing pressures and ramp-up costs.
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 40.8 with a market cap of ₹630 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
The company has invested significantly in R&D, infrastructure, and capacity over the last two years, focusing on projects they anticipate will commercialize in the near future.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.